Bliss GVS Pharma share news, announcements and annual reports
NSE: BLISSGVSBSE: 506197Pharmaceuticals & BiotechnologySmall Cap
Bliss GVS Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1985 on BSE, Jul 2010 on NSE
Last close ₹647.50down ₹33.40 (4.91%)BSE ₹648.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹680.90.
30 Oct: open ₹660.00, high ₹670.00, low ₹646.90
52-week range of traded prices to 30 Oct 2026
₹118.00Low, 10 Nov 2025₹739.90High, 28 Sep 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,885 Cr1,000th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 42.71
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.34
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.23%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 4,45,760
Bliss GVS Pharma board meetings
110 filed, newest first. Page 2 of 3.
Feb 2020
Jan 2020
Nov 2019
Aug 2019
May 2019
18 May · Board meeting
Feb 2019
25 Feb · Board meeting
Jan 2019
30 Jan · Board meeting
Oct 2018
Aug 2018
1 Aug · Board meeting
May 2018
17 May · Board meeting
Jan 2018
19 Jan · Board meeting
12 Jan · Board meeting
4 Jan · Board meeting
Nov 2017
Sep 2017
7 Sep · Board meeting
Aug 2017
May 2017
17 May · Board meeting
Feb 2017
Oct 2016
27 Oct · Board meeting
Jul 2016
May 2016
25 May · Board meeting
Feb 2016
Nov 2015
9 Nov · Board meeting
Oct 2015
Aug 2015
May 2015
30 May · Board meeting
Feb 2015
Oct 2014
31 Oct · Board meeting
Board of Directors of the Company at its meeting held on October 30, 2014, has considered and approved the followings: (1) Enlargement of the object of the Company by inclusion of commodities Trading. (2) Consider, negotiate & finalize purchase of substantial stake in Shree Sales Pack Pvt Ltd ,who presently carries majorities of packaging business for the Company. (3) Consider the proposal of opening office of the Company at London either by setting a subsidiary or representative office.16 Oct · Board meeting
Inter-alia to consider the Unaudited Financial Results of the Company for the quarter ended September 30, 2014.
Jul 2014
30 Jul · Board meeting
To consider interalia, the Un-audited Financial Results of the Company for the Quarter ended June 30, 2014.
May 2014
16 May · Board meeting
To consider interalia:- (1) The Audited Financial Results of the company for the quarter and year ended March 31, 2014; (2) And dividend, if any.
Feb 2014
4 Feb · Board meeting
To Consider interalia, the un-audited Financial Results of the Company for the Quarter ended December 31, 2013.
Nov 2013
6 Nov · Board meeting
To consider interalia, the Un-audited Financial Results of the Company for the Quarter ended September 30, 2013.
Aug 2013
5 Aug · Board meeting
To consider interalia, the Un-audited Financial Results of the Company for the Quarter ended June 30, 2013.
May 2013
29 May · Board meeting
Board of Directors of the Company at its meeting held on May 28, 2013 has approved the following:(1) Renewed the tenure and new salary, terms & conditions, of the Managing Director - Mr. S. N. Kamath and Whole Time Directors - Mrs. Shruti N. Kamath and Mrs. Vibha N. Kamath for a period of three years.22 May · Board meeting
To consider interalia, the audited Financial Results of the company for the year ended March 31, 2013 and dividend, if any.
Feb 2013
6 Feb · Board meeting
To Consider interalia, the un-audited Financial Results of the Company for the Quarter ended December 31, 2012 and Dividend if any.
Nov 2012
1 Nov · Board meeting
To consider, inter alia, the Un-audited Financial Results for the Quarter ended September 30, 2012.